|
|
Post by cedafuntennis on Nov 7, 2023 16:39:55 GMT -5
Get over yourself nemzer. You and my ex wife have to find something negative in anything else positive. Amazing how you can live with yourselves...
|
|
|
|
Post by celo on Nov 7, 2023 16:48:18 GMT -5
20 million was moved from the mid cap long term liability to mid cap short term liability, under liabilities
|
|
|
|
Post by peppy on Nov 7, 2023 16:51:20 GMT -5
Chat Box is open, scroll down.
|
|
rebby
Researcher
Posts: 79
|
Post by rebby on Nov 7, 2023 16:55:08 GMT -5
The dilution (I see it as good if the debt is converted) would translate into needing revenue of ~$800M @ 40% EBITDA to realize $1.00 EPS. If EBITDA is sustained at a higher clip, say 50%, it reduces that revenue threshold significantly (~$640M).
|
|
|
|
Post by casualinvestor on Nov 7, 2023 17:09:34 GMT -5
Comparing numbers Q3 to Q2:
* The revenue increase of $2.6M (~5%) is average-sized news compared to the rest:
* A large increase in R&D of ~$3.5M to almost $10M
* Most costs down a bit overall
* A gain from foreign currency translation to the tune of $2.3M, as compared to a small loss last Q
* A large drop in Interest Expense from $6.9M to $2.8M
What is up with the interest expense? Did something get paid off at the end of Q2?
|
|
|
|
Post by peppy on Nov 7, 2023 17:11:34 GMT -5
Comparing numbers Q3 to Q2: * The revenue increase of $2.6M (~5%) is average-sized news compared to the rest: * A large increase in R&D of ~$3.5M to almost $10M * Most costs down a bit overall * A gain from foreign currency translation to the tune of $2.3M, as compared to a small loss last Q * A large drop in Interest Expense from $6.9M to $2.8M What is up with the interest expense? Did something get paid off at the end of Q2? Steve Binder. |
|
rebby
Researcher
Posts: 79
|
Post by rebby on Nov 7, 2023 17:24:30 GMT -5
Comparing numbers Q3 to Q2: * The revenue increase of $2.6M (~5%) is average-sized news compared to the rest: * A large increase in R&D of ~$3.5M to almost $10M * Most costs down a bit overall * A gain from foreign currency translation to the tune of $2.3M, as compared to a small loss last Q * A large drop in Interest Expense from $6.9M to $2.8M What is up with the interest expense? Did something get paid off at the end of Q2? Steve Binder. Pay that man….he has been working wonders! |
|
|
|
Post by wyattdog on Nov 7, 2023 17:45:42 GMT -5
Great quater and great call now let the negative spin begin.
|
|
|
|
Post by runner on Nov 7, 2023 17:47:05 GMT -5
It was good to hear that Mike talked a lot about growing the business in Europe.
|
|
|
|
Post by castlerockchris on Nov 7, 2023 17:48:24 GMT -5
Are my nov 17 $5 calls still going to be worthless? I hope not, but sadly, I think so. I do wish the half dollar strike priced options become available again. Until they are, or the stock price moves much closer to $5, not much premium to be collected. |
|
|
|
Post by castlerockchris on Nov 7, 2023 17:51:18 GMT -5
Did I hear them correctly on the call when they said they believe they can pay down the debt using cash generated from operations in the coming years?
That would be amazing.
I guess I need to listen to the recording when it become available.
|
|
|
|
Post by Chris-C on Nov 7, 2023 17:57:08 GMT -5
Great call overall. They were clear about the possibility of not having positive GAAP net earnings over the next few quarters because of fluctuating costs and unpredictable exchange rates related to contractual insulin purchases from Germany. For observers like us, Guidance will be influenced by watching exchange rates. Who knew?
Mike sounded pretty positive about expectations related to INHALE study. I like the thinking behind increasing awareness by prescribers through involvement of study sites with endocrinology thought leaders.
All this said, I only expect yawns from the market tomorrow. Did I actually hear Mike apologize for the SP behavior the past week?
Wow. Feeling positive about prospects thru 2025.😊
GLTAL!
|
|
|
|
Post by peppy on Nov 7, 2023 18:07:28 GMT -5
I saw Mike C on this board this am.
One of the slides Mike had for the Earnings call was,
"GLP-1's are not impacting Afrezza."
|
|
|
|
Post by celo on Nov 7, 2023 18:11:53 GMT -5
I think Mannkind is preparing to be able to use shares to buy the 230k of senior convertible notes.
The window to do so opens on March 6, 2024. If the share price has been 6.67 or greater starting around Feb 10th (20 business days prior) then they can buy as much as they want.
I'm ready for the price to be 6.67.
I would think in these times of high interest rates they would want out of this deal. Maybe they will remove their short position and let the share price fly.
Midcap had to begin buy down as of Sept 1. We have had 1 month of buy down of the loan in the third quarter which amounted to 1,667,000 in the CASH FLOWS and FINANCING LIABILITIES. This will be a quarterly draw of 5 million or 20 million annually for the next 2 years.
I have no idea what the owner of the Mann group is doing. Sell your mannkind shares and go earn 5% or higher on that money. You are getting a paltry 2.5%
|
|
|
|
Post by sayhey24 on Nov 7, 2023 18:16:37 GMT -5
I saw Mike C on this board this am. One of the slides Mike had for the Earnings call was, "GLP-1's are not impacting Afrezza." What he needs to outline is HOW is afrezza going to leverage the GLP1. GLP1 are huge and not for BG control. He needs to make GLP1 and afrezza like peanut butter and jelly. He is also sitting on TS and we know Peter Richardson had great success with TS and native GLP1. With Saxenda coming off patent June 2024 I would hope for an announcement July 1. |
|
